Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560733 | 0.84 | TNFRSF1A (0.57) | ERN1TNFRSF1AKDM4EALDH1A1TSHR | |
| SCHEMBL6040896 | 0.81 | TNFRSF1A (0.58) | TNFRSF1APDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6040892 | 0.81 | TNFRSF1A (0.58) | TNFRSF1APDE4DPDE4APDE4BPDE4C | |
| SCHEMBL5559926 | 0.81 | ERN1 (0.49) | ERN1TNFRSF1AKDM4EALDH1A1TSHR | |
| SCHEMBL6040725 | 0.80 | ERN1 (0.50) | ERN1TNFRSF1AKDM4EALDH1A1TSHR | |
| SCHEMBL6040567 | 0.80 | TNFRSF1A (0.49) | ERN1TNFRSF1AALDH1A1SLC6A9 | |
| SCHEMBL6040821 | 0.80 | ERN1 (0.46) | ERN1TNFRSF1AKDM4EALDH1A1TSHR | |
| SCHEMBL6040751 | 0.80 | ERN1 (0.46) | ERN1TNFRSF1AKDM4EALDH1A1TSHR | |
| SCHEMBL6040820 | 0.80 | ERN1 (0.46) | ERN1TNFRSF1AKDM4EALDH1A1TSHR | |
| SCHEMBL6040645 | 0.79 | CHRNB4 (0.43) | ERN1TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | ERN1 1752/4885TNFRSF1A 3846/4885PDE4D 2355/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | ERN1 1076/4885TNFRSF1A 3877/4885PDE4D 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.